Joseph Murphy, Ph.D.
Founder and President Professional Experience Joe is a performance-driven strategist with over 30 years’ experience in biological research in both academia and the biotechnology industry. Prior to immunePCS he has held senior leadership roles including founder and CEO of a biotech company focused on translating novel immune-based anti-cancer therapies into a clinical setting. Most recently he has held directorship roles with contract research organizations (CROs) such as Director of Science (R&D) at Charles River Laboratories, and Director of Cancer Therapeutics and Immunology at Southern Research. |
Joe’s research and development (R&D) strengths span:
- Led pioneering projects focusing on leukocyte endothelial cell interactions, and the anti-angiogenic/tumorigenic effects of cytokine-induced natural killer cells, during post-doctoral fellowships at the Pasteur Institute and Stanford University Medical Center respectively.
- Discovered that endothelial cell receptor ligation induced cyclooxygenase (COX) regulation of angiogenesis and modulation by non-steroidal anti-inflammatory drugs (NSAIDs).
- Conceptualized and established a fully functioning research facility from a green field site and initiating several research projects that included investigating the symbiotic relationship between angiogenesis and cancer, in addition to identifying novel gene candidates for diagnosing and treating pancreatic cancer.
Recent Publications
- Recent Developments of Vaccines as a Precision Medicine Approach to Cancer Immunotherapy. Cancer Screen Prev. 3(2):113-117. doi: 10.14218/CSP.2024.00009. Published June 2024.
- Therapeutic Vaccination and Cancer Immunotherapy. J Explor Res Pharmacol. doi: 10.14218/JERP.2023.00049 Published: September 2023.
- Angiogenesis and the Tumor Microenvironment. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://link.springer.com/referenceworkentry/10.1007/978-3-030-80962-1_87-1 Published: September 2022
- The Human Microbiome and the Tumor Microenvironment. Exploration of Immunology 2:581–588 DOI: https://doi.org/10.37349/ei.2022.00069. Published: August 2022
- Natural Killer Cells: Future Role for Cancer Immunotherapy. International Journal of Pharmaceutical and Bio-Medical Science. Volume 02 Issue 06. https://doi.org/10.47191/ijpbms/v2-i6-01 Published: June 2022
- What's Next for mRNA Vaccines? Nov Res Sci. 10(1). NRS. 000726. https://lnkd.in/d7m6y39w Published: October 2021
- COVID-19 Treatments and Vaccines: A year in Review. International Journal of Immunology and Microbiology, 1(1), 5-9. https://www.sciforce.org/index.php/IJIM/article/view/51. Published: June 2021
- Frontiers in Cancer Immunotherapy (2nd edition). Cancer Immunology-Bench to Bedside. Ed. Nima Rezaei. https://www.springer.com/gp/book/9783030502867. Published: October 2020
- COVID-19: An Immunological Perspective. Published: April 2020
https://medcraveonline.com/MOJI/MOJI-07-00257.pdf - Monocyte and Lymphocyte Membrane Markers: Ontogeny and Clinical Significance. Medical Immunology, 7th edition; Virella. Published: October 2019. https://www.taylorfrancis.com/books/e/9780429278990/chapters/10.1201/9780429278990-10
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for ImmunoTherapy of Cancer. Published: May 2019
https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0602-4 - The human microbiome: an emerging paradigm for better health. MOJ Immunology. Published: April 2018
https://medcraveonline.com/MOJI/MOJI-06-00192.php
- Reverse Translational Medicine: The Promising Future of Failure. BioProcess International. Published: March 2018
https://bioprocessintl.com/business/pre-clinical-and-clinical-trials/elucidation-on-reverse-translational-medicine-the-promising-future-of-failure/ - Immunotherapy of cancers comes of age. Expert Review of Clinical Immunology. 13(10): 1001-1015. Published: August 2017
http://dx.doi.org/10.1080/1744666X.2017.1366315 - Partnering NSAIDs with immunotherapy to fight cancer. Drug Discovery and Development. Published: August 2017
https://www.dddmag.com/article/2017/08/partnering-nsaids-immunotherapy-fight-cancer-0 - Anti-Cancer Therapy: Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in Combination with Immunotherapy. MOJ Immunol 5(3): 00156. Published: March 2017
https://medcraveonline.com/MOJI/MOJI-05-00156.pdf